Calcium channel blocker ingestions in children

M G Belson1, S E Gorman, K Sullivan

  • 1Georgia Poison Center, Emory University School of Medicine, Atlanta, USA. Marty_Belson@oz.ped.emory.edu

Insights

Most pediatric calcium channel blocker (CCB) ingestions result in no or minor toxicity. Asymptomatic children ingesting small amounts of CCBs may be monitored at home, with specific observation times for sustained-release formulations.

Area of Science:

  • Pediatric Toxicology
  • Cardiovascular Pharmacology
  • Poison Control Center Data Analysis

Background:

  • Limited data exists on calcium channel blocker (CCB) toxicity in children.
  • CCB ingestions are a concern for potential cardiovascular and central nervous system effects.

Purpose of the Study:

  • Determine the frequency and range of toxicity from CCB ingestions in children.
  • Establish appropriate observation times and assess effective interventions for pediatric CCB ingestions.

Main Methods:

  • Retrospective review of 283 children younger than 7 years with CCB ingestions reported to a regional poison center over 6 years.
  • Exclusion of patients with co-ingestants causing cardiovascular or CNS effects.
  • Analysis of ingestion amounts, time to symptom onset, and clinical outcomes.

Main Results:

  • Nifedipine, verapamil, and amlodipine were the most common CCBs ingested.
  • 6% of patients experienced symptoms, including vomiting and CNS/cardiovascular effects.
  • 74% of patients had no clinical effects; no deaths or major effects were reported.

Conclusions:

  • Most pediatric CCB ingestions involve small amounts and result in minimal toxicity.
  • Home monitoring may be appropriate for asymptomatic children ingesting specific amounts of sustained-release CCBs.
  • Recommended observation periods are 3 hours for regular-release and 14 hours for sustained-release CCBs.
Abstract

Related Concept Videos

Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...